Satellos Announces Participation in September 2024 Investor Conferences
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), a biotech company developing new small molecule therapeutics for muscle diseases, has announced its participation in two upcoming investor conferences in New York City. CEO Frank Gleeson and CFO Elizabeth Williams will represent the company at these events:
1. H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Wednesday, September 11th at 8:00 a.m. ET
2. Cantor 2024 Global Healthcare Conference: Fireside chat on Thursday, September 19th at 9:45 a.m. ET
Both presentations will be available via live webcast on the company's website, with replays accessible afterwards.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), una azienda biotecnologica che sviluppa nuove terapie a piccole molecole per le malattie muscolari, ha annunciato la sua partecipazione a due prossimi conferenze per investitori a New York City. Il CEO Frank Gleeson e il CFO Elizabeth Williams rappresenteranno l'azienda in questi eventi:
1. H.C. Wainwright 26a Conferenza Globale Annuale sugli Investimenti: discussione informale il mercoledì 11 settembre alle 8:00 a.m. ET
2. Cantor 2024 Conferenza Globale sulla Sanità: discussione informale il giovedì 19 settembre alle 9:45 a.m. ET
Entrambe le presentazioni saranno disponibili tramite webcast dal vivo sul sito web dell'azienda, con le registrazioni accessibili in seguito.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), una empresa biotecnológica que desarrolla nuevas terapias de pequeñas moléculas para enfermedades musculares, ha anunciado su participación en dos próximas conferencias para inversores en la ciudad de Nueva York. El CEO Frank Gleeson y la CFO Elizabeth Williams representarán a la empresa en estos eventos:
1. H.C. Wainwright 26ª Conferencia Global Anual de Inversiones: charla junto a la chimenea el miércoles 11 de septiembre a las 8:00 a.m. ET
2. Cantor 2024 Conferencia Global de Salud: charla junto a la chimenea el jueves 19 de septiembre a las 9:45 a.m. ET
Ambas presentaciones estarán disponibles a través de una retransmisión en vivo en el sitio web de la empresa, con repeticiones accesibles posteriormente.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), 근육 질환을 위한 새로운 소분자 치료제를 개발하는 생명공학 회사,가 뉴욕시에서 열리는 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. CEO 프랭크 글리슨과 CFO 엘리자베스 윌리엄스가 이 행사에서 회사를 대표합니다:
1. H.C. Wainwright 제26회 글로벌 투자 회의: 9월 11일 수요일 오전 8시 (ET)의 화상 대담
2. Cantor 2024 글로벌 헬스케어 회의: 9월 19일 목요일 오전 9시 45분 (ET)의 화상 대담
두 발표는 회사 웹사이트에서 실시간 웹캐스트 형식으로 제공되며, 이후 다시 시청할 수 있습니다.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), une entreprise biotechnologique développant de nouveaux thérapeutiques à petites molécules pour les maladies musculaires, a annoncé sa participation à deux conférences pour investisseurs à venir à New York City. Le PDG Frank Gleeson et la CFO Elizabeth Williams représenteront l'entreprise lors de ces événements :
1. H.C. Wainwright 26ème Conférence Globale Annuelle d'Investissement : discussion informelle le mercredi 11 septembre à 8h00 ET
2. Cantor 2024 Conférence Globale sur la Santé : discussion informelle le jeudi 19 septembre à 9h45 ET
Les deux présentations seront disponibles par webcast en direct sur le site web de l'entreprise, avec des rediffusions accessibles par la suite.
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF), ein Biotechnologieunternehmen, das neue kleine Molekültherapeutika für Muskelerkrankungen entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen in New York City bekannt gegeben. CEO Frank Gleeson und CFO Elizabeth Williams werden das Unternehmen bei diesen Veranstaltungen vertreten:
1. H.C. Wainwright 26. jährliche globale Investorenkonferenz: Gespräch am Mittwoch, 11. September um 8:00 Uhr ET
2. Cantor 2024 globale Gesundheitskonferenz: Gespräch am Donnerstag, 19. September um 9:45 Uhr ET
Beide Präsentationen werden über einen Live-Stream auf der Website des Unternehmens verfügbar sein, mit späteren Aufzeichnungen, die ebenfalls zugänglich sind.
- Participation in two major investor conferences, potentially increasing visibility and investor interest
- Live webcast availability of presentations, enhancing accessibility for investors
- None.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Date: Wednesday, September 11th at 8:00 a.m. ET
Cantor 2024 Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 19th at 9:45 a.m. ET
The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website and a replay will be available following the presentations.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenXTM, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905313758/en/
Investors: Liz Williams, ir@satellos.com
Business Development: Ryan Mitchell, Ph.D., bd@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com, +1.858.344.8091
Source: Satellos Bioscience Inc.
FAQ
When is Satellos Bioscience (MSCLF) participating in the H.C. Wainwright Global Investment Conference?
What is the date and time of Satellos Bioscience's (MSCLF) presentation at the Cantor 2024 Global Healthcare Conference?
Who will be representing Satellos Bioscience (MSCLF) at the September 2024 investor conferences?
How can investors access Satellos Bioscience's (MSCLF) presentations at the September 2024 conferences?
